Aridis Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of novel, differentiated therapies for infectious diseases. Complementing the product pipeline is a disruptive platform technology to discover rare, potent human monoclonal antibodies from patients. Our scientists and leadership team have a proven track record of innovation and successful drug development of therapeutic candidates from early discovery to commercial implementation. The Companyâs mission is to introduce much needed innovations to infectious disease treatment using an anti-infective product portfolio that includes four (4) clinical stage and two preclinical drug candidates. Our antimicrobial product candidates are highly differentiated from conventional antibiotics in mechanisms of action, and are being developed using clinical study designs that allow for clear demonstration of superiority over standard of care antibiotics. Source
No articles found.
BioCryst Pharmaceuticals discovers novel, oral small-molecule medicines that treat...
BioCryst Pharmaceuticals discovers novel, oral ...
Tocagen is a clinical-stage, cancer-selective gene therapy company developing firs...
Tocagen is a clinical-stage, cancer-selective g...
Akari is a biopharmaceutical company focused on developing inhibitors of acute and...
Akari is a biopharmaceutical company focused on...
ArQule is a biopharmaceutical company engaged in the research and development of t...
ArQule is a biopharmaceutical company engaged i...
Citius Pharmaceuticals is a specialty pharmaceutical company dedicated to the deve...
Citius Pharmaceuticals is a specialty pharmaceu...
BeiGene, Ltd. (âBeiGeneâ) is a commercial-stage biotechnology company focused ...
BeiGene, Ltd. (âBeiGeneâ) is a commercial-s...
Chembio is a leading point-of-care diagnostics company focused on detecting and di...
Chembio is a leading point-of-care diagnostics ...
Join the National Investor Network and get the latest information with your interests in mind.